Azactum

• Urinary tract infections (cystitis, pyelonephritis)
• Lower respiratory tract infections (pneumonia)
• Intra-abdominal infections (peritonitis)
• Skin and soft tissue infections
• Gynecological infections (pelvic inflammatory disease)
• Septicemia
• Bone and joint infections
• Meningitis
• Pseudomonas aeruginosa infections in cystic fibrosis
• Infections in penicillin-allergic patients

Aztreonam inhibits bacterial cell wall peptidoglycan synthesis. It binds to penicillin-binding protein 3 (PBP-3), which plays a crucial role in cell division and wall formation in gram-negative bacteria. This leads to cell wall weakening and bacterial lysis.

Adults: 1-2 g every 8-12 hours; severe infections: 2 g IV every 8 hours.

Pediatrics: 30-50 mg/kg every 8 hours, not to exceed adult dose. Neonates and infants: careful dose adjustment needed.

Renal dose: CrCl 10-30 mL/min: 1-2 g loading dose, then 50% of usual dose; CrCl <10 mL/min: 1-2 g loading dose, then 25% of usual dose.

• Rash
• Injection site reactions (pain, swelling, redness)
• Vomiting
• Nausea
• Diarrhea
• Cough
• Nasal congestion
• Wheezing
• Sore throat
• Pyrexia
• Chest discomfort
• Abdominal pain

Rare: Anaphylaxis, angioedema, bronchospasm, pancytopenia, neutropenia, thrombocytopenia

[SAFE IF PRESCRIBED] Aztreonam is generally considered safe during pregnancy (Pregnancy Category B). Animal studies have not shown fetal risk. Use only if clearly needed.

• Discontinue immediately if hypersensitivity reactions (anaphylaxis, angioedema) occur
• Prolonged use may lead to superinfection
• Caution in patients with allergy to penicillin or other beta-lactams
• Caution during pregnancy and lactation

In case of overdose, provide symptomatic and supportive treatment.

Reconstituted solution is stable for 48 hours at 15-30°C and 7 days at 2-8°C. Store in original packages at 20-25°C.